Cyclooxygenase (COX)-2 is a central enzyme of arachidonic acid metabolism, and its modulation by statins may explain some of the myocardial protective effects of these drugs. Dendritic cells (DCs) play a central role in microbial defense and in atherogenesis, and COX-2 expression in DCs is important for their migration to lymph nodes and antibody response, thus explaining why prostaglandin E 2 is a main component of the cocktails used to prepare DCs for clinical applications. On this basis, we addressed the effect of atorvastatin (ATV) on the release of arachidonic acid and on the expression of COX-2 in human monocyte-derived DCs. Although ATV on its own lacked any effect on COX-2 protein induction expression, it enhanced the release of arachidonic acid, the expression of COX-2 protein, and the production of prostaglandin E 2 induced by the fungal wall extract zymosan, and to a lower extent the effect of peptidoglycan. The effect on COX-2 protein was observed mainly 24 h after stimulation by zymosan and was not reverted by mevalonate, thus pointing to an effect unrelated to cholesterol metabolism. It is noteworthy that COX-2 protein showed a great stability, with a t 1 ⁄2 of approximately 12 h, which was enhanced in the presence of ATV. In view of the important role played by COX-2 on DC function, these data indicate that ATV, by enhancing COX-2 stability, may increase DC function after infectious bouts and also counteract some of the risks associated with sustained inhibition of COX-2.
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Atorvastatin (ATV) is a member of the class of drugs called statins, the main use of which is the reduction of cholesterol plasma levels and the prevention of the complications associated with atheromatosis (Nawrocki et al., 1995) . The mechanism of action of ATV is the competitive inhibition of the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), which catalyzes the reduction of 3-hydroxy-3-methylglutarylCoA to mevalonate. Because this is the limiting step of cholesterol synthesis by the liver, ATV reduces the hepatic synthesis of cholesterol and increases the expression of lowdensity lipoprotein receptors. In addition to the effects on cholesterol plasma levels, statins show additional beneficial properties (Kwak et al., 2000) , among them various antiinflammatory effects and a modification of the pattern of gene expression in several cell types. For instance: 1) statins have been found to reduce the expression of several vascular adhesion molecules that take part in the initial phases of leukocyte adherence to endothelial cells (Marschang et al., 2006) , 2) statins reduce the expression of the chemokines involved in the mechanisms of leukocyte recruitment into the subendothelial space (Rezaie-Majd et al., 2002) , and 3) statins modulate the effect of matrix metalloproteinases via the regulatory molecule TIMP-1 (Ikeda et al., 2000) . Experimental studies with ATV have disclosed an increase of the expression and activity of both cytosolic phospholipase A 2 (cPLA 2 ) and cyclooxygenase (COX)-2 in rat hearts and the production of the anti-inflammatory 15-epi-lipoxin A 4 and have suggested that this might be a central mechanism ex-plaining their anti-inflammatory effects (Birnbaum et al., 2006) . Moreover, clinical studies have disclosed the immunomodulatory effect of atorvastatin as judged from the lower incidence of rejection episodes in patients on statin treatment who underwent heart transplantation (Kobashigawa et al., 1995) .
Despite the variety of pharmacological properties of statins reported so far, it seems likely that other effects of statins remain uncharacterized and might be of potential application for the employment of ATV. It is now accepted that the inflammatory reaction associated with the activation of pattern recognition receptors for pathogen-associated molecular patterns expressed on macrophages and dendritic cells (DCs) is a relevant pathogenic mechanism in atherogenesis. Although the role of Toll-like receptors has been explored widely in different leukocyte subsets (Mullick et al., 2006; Weber et al., 2008) , the role of pattern recognition receptors expressed in DCs in atherogenesis is less known, although it has been reported recently that they are the most abundant cell type in intimal areas prone to develop atherosclerosis (Doherty et al., 2006; Jongstra-Bilen et al., 2006) .
The effect of statins on the signaling function of cell lipids can be exerted at different levels. For instance, statins reduce the stability of lipid rafts and prevent the prenylation of signaling molecules with subsequent downregulation of cytokine, chemokine, and adhesion molecule gene expression (Hillyard et al., 2007) . Another example is the arachidonic acid (AA) cascade, which produces eicosanoids from the AA released from membrane phospholipids by a phospholipase A 2 -catalyzed reaction. This yields an array of lipids that may exert both proinflammatory and anti-inflammatory effects. In the particular case of DCs, prostaglandin E 2 is a major factor involved in the induction of maturity (Jonuleit et al., 1997) , in the migration to the lymph nodes (van Helden et al., 206) , and in the antibody (Ab) response (Ryan et al., 2006) .
In previous studies conducted on human monocyte-derived DCs, we have analyzed the responses elicited by bacterial and fungal stimuli (Valera et al., 2008) . These responses can be integrated in two distinct patterns: 1) bacterial lipopolysaccharide (LPS) stimulates IL-10 and IL-12 p70 responses and induces COX-2 or prostaglandin endoperoxide H synthase-2; and 2) the fungal wall extract zymosan, a surrogate of fungal particles, shared with LPS the ability to induce COX-2 and IL-10, whereas it showed a limited ability to generate IL-12 p70.
PGE 2 plays a central role in DC biology because it is necessary for podosomal dissolution and induction of highspeed migration during maturation (van Helden et al., 2006) . Because a lasting induction of COX-2 expression is produced by zymosan, it seems likely that this represents an autocrine mechanism of PGE 2 production necessary for DC migration. Taking these data into account and the pharmacological benefit of ATV in many systems, we have addressed the effect of ATV on the induction of COX-2 in response to bacterially and fungally related stimuli in human monocyte-derived DCs. We have observed that ATV, by enhancing COX-2 protein stability, might increase DC function and counteract some of the untoward effects associated with sustained inhibition of COX-2.
Materials and Methods
Reagents. Zymosan and mannan from Saccharomyces cerevisiae, OptiPrep, Escherichia coli LPS, mevalonate, mannan from S. cerevisiae, peptidoglycan from Staphylococcus aureus, and AA were from Sigma-Aldrich (St. Louis, MO). Anti-human CD206/MR and antihuman CD209/DC-SIGN monoclonal Abs were from BD Biosciences Pharmingen (San Diego, CA). Goat anti-dectin-1 Ab was from R&D Systems (Minneapolis, MN). Endotoxin levels in the reagents were below 1 ng/ml as determined by the Limulus Amebocyte Lisate assay (Lonza Walkersville, Inc., Walkersville, MD). Atorvastatin was provided by Pfizer Inc. (Groton, CT). Final concentrations of ethanol to solubilize arachidonic acid and DMSO to solubilize atorvastatin were 1:1000 (v/v).
Harvesting of Monocyte-Derived DCs. Mononuclear cells were collected from buffy coats of healthy donors by centrifugation on Ficoll-Hypaque cushions. The mononuclear cell ring was recovered in 3 ml of OptiPrep (Sigma-Aldrich) and then layered below a solution of 7 ml of Ficoll (density, 1.072 g/ml). A discontinuous gradient was formed by adding a solution of OptiPrep (density, 1.068 g/ml) containing 0.5% bovine serum albumin (BSA) and 1 mM EDTA, followed by a HEPES-buffered saline solution. The mixture was centrifuged for 25 min at 725g at 19°C, and the lymphocyte-depleted cell solution was collected and treated again to enhance the purity of the cell preparation. Cells were maintained for 2 h at 37°C to allow the adherence of monocytes. Nonadhered cells were removed, and the remaining cells were cultured in the presence of granulocyte macrophage-colony stimulating factor (800 U/ml) and IL-4 (500 U/ml) for 5 days. DC differentiation was assessed by flow cytometry of CD40, CD80, CD83, and CD86.
Metabolic Real-Time RT-PCR and Western Blot. Real-time RT-PCR was carried out to monitor the changes of expression of COX-2 mRNA. Genomic DNA was eliminated by treatment with DNase (Turbo-DNA free; Ambion, Austin, TX), and the remaining RNA was used for reverse transcription reactions. The resulting cDNA was amplified in a PTC-200 Peltier thermal cycler with Chromo4 detector (Bio-Rad, Hercules, CA) using SYBR Green I mix containing Hot Start polymerase (ABgene, Epsom, Surrey, UK). DNA primers were selected from exons 1 and 2 (Ferná ndez et al., 2007) . Glyceraldehyde-3-phosphate dehydrogenase was used as a housekeeping gene. The relative expression of COX-2 mRNA was assessed by the threshold cycle (CT). This method allows the calculation of mRNA relative expression of a given gene using the formula: 2 Ϫ⌬CT , where ⌬C T ϭ ⌬C T COX-2 Ϫ ⌬C T housekeeping gene . According to this expression, 1 arbitrary unit corresponds to the expression of the constitutive gene, and the changes induced by the different treatments can be expressed according to the ratio 2 Ϫ⌬⌬CT (Pfaffl, 2001) . Primers for the detection of COX-1 mRNA were: forward, 5Ј-GCTCTGGTTCTTGCTGTTCC-3Ј; and reverse, 5Ј-GTTGGA-GCGCACTGTGAGTA-3Ј. Protein immunodetection was carried out by standard techniques. In brief, proteins were separated by electrophoresis in SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were used for immunodetection of COX-2 with a goat Ab (SC-1745) and COX-1 with a rabbit Ab (SC-7950) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-cPLA 2 Ab was from Cell Signaling Technology Inc. (Danvers, MA). Quantitation of the blots was conducted using Bio-Rad Quantity One gel imaging software (Bio-Rad).
Results

ATV Does Not Modify Immature DC Surface Markers and Enhances [
3 H]AA Release from DCs Stimulated with Zymosan. Because DC function depends on the surface display of costimulatory molecules and particle uptake receptors, the effect of ATV on the expression of these markers was assayed by flow cytometry immunofluorescence. As shown in Fig. 1A , the expression of CD206 (mannose receptor), CD209/ DC-SIGN, CD40, CD80, CD83, and CD86 was not signifi- jpet.aspetjournals.org cantly affected by ATV treatment, both in the presence and absence of zymosan. The expression of dectin-1 showed a marginal decrease in the absence of zymosan, which did not reach statistical significance, thus ruling out a major effect of ATV on the expression of molecules involved in both antigen uptake and generation of costimulatory signals. Zymosan is the most active stimulus for AA release from cell membranes in DCs and acts through recognition by the C-type lectin receptors DC-SIGN and dectin-1 (Suram et al., 2006; Valera et al., 2008) , Toll-like receptor 2 (Underhill et al., 1999; Brown et al., 2003; Gantner et al., 2003) , and the mannose receptor (de la Rosa et al., 2005; Netea et al., 2006) . For this reason, zymosan was selected as a stimulus for the study of the effect of ATV on AA metabolism in DCs. As shown in Fig.  1B , incubation of DCs with 10 M ATV for 48 h produced a detectable increase of [ 3 H]AA release in resting cells and enhanced the response to zymosan. This effect was reverted by 100 M mevalonate, which on its own showed a nonsignificant effect on [ 3 H]AA release and suggests an effect related to the action of ATV on HMGR. Because it has been reported that ATV enhances the production of eicosanoids by promoting the induction of cPLA 2 in rat cardiomyocytes (Birnbaum et al., 2005) , the possible effect of ATV on this enzyme was addressed in the presence of different additions 30 min after stimulation with zymosan. As shown in Fig. 1C , zymosan induced a shift of the electrophoretic mobility of cPLA 2 , which is consistent with the reported phosphorylation of cPLA 2 by different elements of the mitogen-activated protein kinase family (Lin et al., 1993; Kramer et al., 1996; Herná ndez et al., 1997) ; however, the amount of protein was similar in control and ATV-treated cells, both in the presence and absence of zymosan, thus indicating that the effect of ATV on [ 3 H]AA release cannot be explained by an enhanced expression of cPLA 2 .
Effect of ATV on COX-2 Induction. Initial experiments were conducted by incubating immature DCs for 48 h with 1 M ATV, followed by stimulation for 8 h with archetypal agonists of pattern recognition receptors such as zymosan, peptidoglycan, LPS, and mannan. As shown in Fig. 2A , although ATV on its own lacked any effect on COX-2 protein induction, it produced a remarkable enhancement of the expression of COX-2 induced by 1 mg/ml zymosan particles. This effect was less marked in response to other stimuli, which in fact were less active than zymosan in promoting COX-2 induction. Attempts to use other concentrations of ATV were carried out by testing 10 M ATV and a preincubation period of 30 min, followed by a stimulation period of 24 h. As shown in Fig. 2B , this administration protocol confirmed the results observed with the previous dosage schedule because ATV increased zymosan and the peptidoglycan effect. Taking these findings into account, zymosan was selected as a stimulus for further study, and preincubation with 10 M ATV was carried out for 30 min. In keeping with our previous report (Valera et al., 2008) , the zymosan effect was characterized by a prolonged induction of COX-2 protein in DCs because it was detectable 4 h after the addition of the stimulus and remained detectable for at least 72 h. ATV effect was characterized by an increase of COX-2 induction that was most prominent at late times (Fig. 3A) . To address whether the effect of ATV is related to the enzymic activity of HMGR, some experiments were carried out in the presence of 100 M mevalonate. As shown in Fig. 3B , the enhancing effect of ATV again was more marked after longer periods of incubation with zymosan, as judged from the higher amounts of protein at 24 and 48 h in the presence of ATV. It is notable that the effect of ATV was not significantly influenced by the addition of 100 M mevalonate, which would suggest that this effect of ATV is not dependent on its effect on HMGR. To address whether the effect of ATV on COX-2 protein can be explained by an effect on COX-2 transcription, the levels of COX-2 mRNA in the presence and absence of ATV were measured at different times after zymosan addition. As shown in Fig. 4A , zymosan induced a rapid and lasting increase of COX-2 mRNA, which decreased after 24 h. It is surprising that COX-2 mRNA levels in the presence of ATV were lower at all time points, thereby suggesting that the effect of ATV cannot be explained by an effect on COX-2 Fig. 2 . Effect of ATV on COX-2 protein induction elicited by different stimuli. Immature DCs were incubated for 48 h with 1 M ATV or vehicle and then stimulated for 8 h with 1 mg/ml zymosan (zym), 30 g/ml peptidoglycan (PGN), 25 mg/ml mannan, and 10 g/ml LPS. At the end of this period, DCs were collected and used for the immunodetection of COX-2 protein (A). A similar experiment was conducted in cells incubated in the presence of 10 M ATV for 30 min and stimulated for 24 h with zymosan and PGN at the same concentrations (B). The amount of protein loaded in the different lanes was assessed by using anti-␤-actin monoclonal Ab. Blots are representative of three independent experiments. ‫,ء‬ P Ͻ 0.05. transcription. Because COX-1 has been found to be inducible under certain conditions and it contributes to PGE 2 production in DCs (Valera et al., 2008) , the effect of ATV on COX-1 expression was studied. However, neither ATV nor zymosan did modify the expression of COX-1 protein, which was detected as a double band in DCs, most likely because of the presence of both glycosylated and nonglycosylated protein, both in the presence and absence of ATV (Fig. 4B ). In keeping with this finding, the expression of the mRNA of COX-1 was not influenced by the treatments (Fig. 4B) .
The production of PGE 2 elicited by zymosan was enhanced in DCs pretreated with ATV, and this increase was observed even in the presence of mevalonate, which indicates that the enhanced induction of COX-2 protein is not dependent on an effect on HMGR and leads to an increased production of PGE 2 (Fig. 4C) . Unlike COX-1, COX-2 protein is characterized by the presence of an instability motif (27-IM) near the C terminus, Fig. 3 . Effect of ATV on COX-2 protein induction elicited by zymosan: time course. Immature DCs were incubated with 10 M ATV for 30 min and stimulated with 1 mg/ml zymosan for the times indicated. The expression of ␤-actin was used as a load control for the normalization of densitometric scanning. This is a representative experiment of three with identical trend (A). Effect of mevalonate treatment on the action of ATV on COX-2 protein induction. DCs were incubated with 100 M mevalonate and/or 10 M ATV for 30 min before zymosan addition. At the end of this period, DCs were collected at the times indicated and used for the immunodetection of COX-2 protein. This is a representative experiment of three densitometrically analyzed independent experiments (B). ‫,ء‬ P Ͻ 0.05. Fig. 4 . Effect of ATV on the expression of COX-2 and COX-1 in DCs treated with different additions. Immature DCs were incubated in the presence and absence of 10 M ATV, and at the times indicated, the expression of COX-2 mRNA was detected by real-time RT-PCR, quantitated as described under Materials and Methods, and expressed after normalization for glyceraldehyde-3-phosphate dehydrogenase expression. This is a representative experiment with duplicate samples of three with identical trend (A). The effect of ATV on the induction of COX-1 protein and mRNA is shown in B. COX-1 protein was assayed after 8 h of incubation with 1 mg/ml zymosan, 30 g/ml PGN, and 10 g/ml LPS in the presence of the indicated concentrations of ATV. The RT-PCR assay of the mRNA encoding COX-1 was conducted in DCs stimulated for 3 h with zymosan in the presence and absence of ATV. The effect of ATV on the production of PGE 2 by DCs stimulated for 48 h with 1 mg/ml zymosan is shown in C. Results in C represent mean Ϯ S.E.M. of six independent experiments with duplicate samples. ‫,ء‬ P Ͻ 0.05.
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at ASPET Journals on July 11, 2017 jpet.aspetjournals.org which accounts for the transient nature of COX-2 induction in most cells (Smith, 2008) . To address whether the effect of ATV could be explained by an effect on the stability of COX-2 protein, experiments were conducted in the presence of the translation inhibitor cycloheximide. When DCs were incubated in the presence of 150 M cycloheximide before the addition of zymosan, no protein induction was observed (Fig.  5A, inset) , which indicates the effectiveness of this concentration of cycloheximide to inhibit COX-2 translation in this cell system. In sharp contrast, incubation of DCs in the presence of cycloheximide added to the medium 8 h after zymosan was characterized by a slow decay of the protein (t 1 ⁄2 ϳ12 h), as shown in Fig. 5A expressing the results as percentage on the initial amount of protein. It is notable that this decay was less pronounced in the presence of ATV, particularly at late times. These findings indicate a slow decay of COX-2 protein in DCs compared with most cell systems, where t 1 ⁄2 is ϳ3 h (Mbonye et al., 2008) , and an enhanced stability in the presence of ATV. Because another mechanism of COX-2 decay has been related to substrate turnover, suicide inactivation, and protein denaturation, experiments were performed in the presence of a high concentration of exogenous AA. As shown in Fig. 5B , addition of 50 M AA for 12 h to DCs previously stimulated for 8 h with zymosan produced a minimal change of COX-2 protein expression, whereas in DCs treated with vehicle, COX-2 protein expression slightly increased within this time frame (Fig. 5B) . When the experiment was carried out in the presence of ATV (Fig. 5C) , the decay of COX-2 protein induced by AA was similar to that detected in the presence of vehicle, which suggests that the effect of ATV cannot be associated with a protective effect on suicide inactivation. Taken collectively, these data indicate that, although the slow decay of COX-2 protein in DCs can be explained by mechanisms dependent on both protein instability and substrate turnover, the capacity of ATV to prolong COX-2 t 1 ⁄2 seems most likely exerted on the instability of the protein, which involves its transport to the cytoplasm via the endoplasmic reticulum (ER) and the ER-associated degradation system and depends on the instability motif (27-IM) (Smith, 2008) .
Discussion
The present data show a net ability of ATV to enhance both the release of AA and the induction of COX-2 protein in human monocyte-derived dendritic cells stimulated with zy- mosan particles, a surrogate of fungal cell wall mainly composed of ␤-glucans and ␣-mannans that are recognized by receptors on DC membranes. Although dectin-1 is the ␤-glucan receptor (Brown et al., 2003; Gantner et al., 2003) , DC-SIGN interacts with mannose residues (Geijtenbeek et al., 2000) . It is notable that with the exception of peptidoglycan, we have been unable to show a similar effect on DCs stimulated with other stimuli; for instance, bacterial lipopolysaccharide and mannan from S. cerevisiae. An explanation for these findings could be that zymosan is the strongest stimulus for this particular response and this allows a more definite appraisal of the changes. Alternatively, ATV might influence specific signaling routes involved in zymosan response or act at a time after zymosan addition where the effect of other stimuli on COX-2 protein induction is less prominent because ATV effect is most remarkable 24 h after zymosan addition and can be observed for at least 72 h. These results agree with previous studies in rat cardiomyocytes, where it has been reported the ability of ATV to induce cPLA 2 (Birnbaum et al., 2005) and COX-2 protein and protect from ischemia (Birnbaum et al., 2006 ). In the current study, the effect on [
3 H]AA release was observed even in the absence of zymosan; however, ATV alone was unable to induce both cPLA 2 and COX-2 protein in DCs, the presence of zymosan being necessary to disclose the enhancing effect on COX-2 protein expression in DCs. In addition, ATV did not influence the mobility shift of cPLA 2 produced by zymosan, which is explained by the phosphorylation by mitogen-activated protein kinases and is a good surrogate of the involvement of the cPLA 2 route. This is somewhat different from what has been reported in myocardial cells because ATV alone induced the expression of COX-2 protein in the absence of any stimulus (Birnbaum et al., 2006 ).
An effect of statins on [ 3 H]AA release has been reported in rat liver cells previously (Levine, 2003) ; however, concentrations of drugs higher than those used in the present study were necessary, e.g., 50 M simvastatin. This effect was observed in the presence of either mevalonate or actinomycin, which indicated an effect independent of cholesterol metabolism and of transcription. In contrast, we observed a higher sensitivity of DCs to release [ 3 H]AA in the presence of ATV and inhibition by mevalonate. Because cPLA 2 is under resting conditions in the cytosol and only after cell stimulation locates to internal membranes, it seems likely that ATV might be acting by favoring enzyme/substrate interaction (Ye et al., 2008) .
With regard to the mechanism whereby ATV exerts its effect on COX-2, several possibilities can be considered involving both mRNA and protein expression. On the one hand, COX-2 mRNA levels depend on COX-2 mRNA transcription and on COX-2 mRNA stability. On the other hand, COX-2 protein levels are influenced by the stability of the protein (Smith, 2008) , and regulation of COX-2 mRNA translation by the mammalian target of rapamycin route has been reported during the stimulation of human polymorphonuclear leukocytes with mannan and peptidoglycan (Ferná ndez et al., 2007) . This mechanism is termed signal-dependent activation of mRNA translation and has been reported to explain the synthesis of proteins without a requirement for enhanced transcription (Lindemann et al., 2004) . Moreover, splicing and translation of little processed COX-2 RNA is rapidly induced upon LPS treatment of human platelets (Shashkin et al., 2008) . Because zymosan-induced COX-2 mRNA expression decreased in the presence of ATV, our findings suggest an effect on COX-2 translation and/or stability.
COX-2 protein stability is of great importance to control COX-2 protein levels because COX-2 degradation is programmed to limit the amount of enzyme and COX-2 overexpression in vivo is associated with pathologies, such as colon cancer (Smith, 2008) . It is notable that COX-2 is embedded in the luminal surface of the endoplasmic reticulum (Spencer et al., 1998) , and a mechanism for COX-2 degradation involves its transport to the cytoplasm via the ER-associated degradation system, followed by ubiquitination and proteolysis by the 26S proteasome (Mbonye et al., 2008) . It seems likely that ATV could influence the association of COX-2 to the ER and then interfere with stability because ATV could influence the composition of the ER lipid bilayer because of its effects on lipid metabolism. However, our experiments in the presence of cycloheximide indicate that ER-associated degradation of COX-2 in DCs occurs at a low speed because cycloheximide only abrogated COX-2 expression completely when administered before zymosan stimulation, thus proving that, although it does block new protein biosynthesis, a substantial portion of COX-2 protein remains in DCs after COX-2 biosynthesis blockade. This indicates a lasting stability of the protein, which shows a t 1 ⁄2 much longer than that observed in other cell systems (Mbonye et al., 2008) . Another mechanism of COX-2 degradation is linked to substrate turnover, suicide inactivation, and attendant denaturation, which is different from the aforementioned mechanism involving the 27-IM domain characteristic of COX-2 and absent in COX-1. To explore this mechanism, we incubated DCs in the presence of 50 M AA with the purpose of addressing the effect of a high concentration of substrate on COX-2 protein expression. Again, AA induced a limited effect on COX-2 protein stability, and the only difference observed in vehicle-treated DCs compared with control cells was a stabilization of the amount of COX-2 protein versus a slight increase during the 12 h that followed the addition of zymosan, which is most likely explained by the lasting induction of protein after zymosan addition. These findings support again the stability of COX-2 protein in DCs and point to an effect of ATV on COX-2 instability unrelated to the decay produced by its catalytic activity. ATV actions can be exerted via its effects on cholesterol metabolism or by other mechanisms. Because the effects were still observed in the presence of mevalonate, the product of the HMGR reaction, our results suggest an effect not directly related to its action on cholesterol metabolism.
These findings can be of physiological relevance because PGE 2 and PGD 2 are the most relevant eicosanoids derived from DCs through the COX routes and display important functions on DC function. In fact, PGE 2 induces podosome disassembly and high-speed migration during DC maturation (van Helden et al., 2006; Lehner et al., 2008) . This is observed within minutes after stimulation and is mediated by cyclic AMP elevation, activation of the RhoA/Rho kinase axis, and actomyosin-based contraction. A proof-of-concept of the clinical relevance of these findings is the use of PGE 2 as a main component of what is now regarded as the "gold standard" method to prepare DCs for clinical studies (Jonuleit et al., 1997) . Moreover, COX-2 seems to play an important function during the immune response by enhancing Ab production after vaccination, particularly when vacAtorvastatin, Cyclooxygenase, and Dendritic Cells 993 at ASPET Journals on July 11, 2017 jpet.aspetjournals.org cines are poorly immunogenic or the target population is poorly responsive to immunization, as it has been demonstrated after immunization with human papillomavirus-like particles (Ryan et al., 2006) . Because ATV on its own does not induce COX-2, the present results suggest that ATV, through its enhancing effect on microbial-like stimuli-induced COX-2 expression, might speed DC migration after fungal invasion and enhance Ab response. Because increased ATV-induced COX-2 expression contributes to the production of anti-inflammatory 15-epi-lipoxin A 4 in heart tissue (Birnbaum et al., 2006) , our data suggest that ATV might tune the immune response in a way where DC migration to the lymph nodes and Ab response after infectious bouts might be selectively increased, whereas other proinflammatory events usually associated with COX-2 induction are down-regulated. It is notable that COX-2 inhibition may compromise reverse cholesterol transport and favors the transformation of monocytic cells in foam cells, thereby contributing to the increased cardiovascular risk in patients treated with COX-2 inhibitors (Chan et al., 2007) . On this basis, the preserving effect of ATV on the COX-2 protein might be an additional mechanism whereby ATV exerts its antiatherogenic effects and could counteract some of the untoward consequences of chronic COX-2 inhibition.
